Cetuximab biosimilar - Oncobiologics

Drug Profile

Cetuximab biosimilar - Oncobiologics

Alternative Names: ONS-1055

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncobiologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer; Head and neck cancer

Highest Development Phases

  • No development reported Colorectal cancer; Head and neck cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (IV, Infusion)
  • 14 Mar 2014 Cetuximab biosimilar - Oncobiologics is available for licensing as of 07 Aug 2013. http://oncobiologics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top